Ticho Barry 4
4 · Stoke Therapeutics, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
Stoke Therapeutics CMO Ticho Barry Receives Equity Awards
What Happened
Ticho Barry, Chief Medical Officer of Stoke Therapeutics (STOK), was granted a total of 100,000 derivative equity awards on February 17, 2026: a 60,000-share option award and a 40,000-share restricted stock unit (RSU) award. Both awards are reported as granted at $0 (i.e., non-cash compensation awards rather than open-market purchases or sales).
Key Details
- Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (appears to be within the two-business-day reporting window).
- Awards: 60,000 (option-type award) and 40,000 RSUs; acquisition price reported as $0.
- Vesting (per footnotes):
- Options: vest 1/48 of total on March 15, 2026, then 1/48 each monthly anniversary thereafter (monthly vesting).
- RSUs: vest 1/4 annually with first tranche on February 15, 2027 (annual cliff vesting).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Filing type: Grant/Award (transaction code A). No 10b5-1 plan, tax-withholding sale, or other sale/exercise noted in the excerpt.
Context
These are compensation grants (derivative awards) rather than purchases or sales; options give the right to buy shares subject to a vesting schedule, and RSUs convert to shares upon settlement after vesting. Such awards are routine for executives and reflect company compensation, not immediate insider buying or selling.
Insider Transaction Report
- Award
Employee Stock Option (Right to Buy)
[F1]2026-02-17+60,000→ 60,000 totalExercise: $31.09Exp: 2036-02-16→ Common Stock (60,000 underlying) - Award
Restricted Stock Units
[F2][F3]2026-02-17+40,000→ 40,000 totalExp: 2030-02-15→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
- [F3]The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.